Effects of cardiac-restricted overexpression of the A2A adenosine receptor on adriamycin-induced cardiotoxicity

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 298, Issue 6, 2010, Pages

  Hamad, Eman A ^a   Li, Xue ^a   Song, Jianliang ^a   Zhang, Xue Qian ^a   Myers, Valerie ^a   Funakoshi, Hajime ^a   Zhang, Jin ^a   Wang, JuFang ^a   Li, Jifen ^a   Swope, David ^a   Madonick, Ashley ^a   Farber, John ^a   Radice, Glenn L ^a   Cheung, Joseph Y ^a   Chan, Tung O ^a   Feldman, Arthur M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Ca2+ i transients; Action potential duration; Cardiac myocytes; Cardiomyopathy

Indexed keywords

ADENOSINE A2A RECEPTOR; CALCIUM; CONNEXIN 43; NERVE CELL ADHESION MOLECULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRADYCARDIA; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART BLOCK; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART PROTECTION; MEMBRANE DEPOLARIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QT PROLONGATION; SUDDEN DEATH; TELEMETRY; TRANSGENIC MOUSE; WILD TYPE;

ACTION POTENTIALS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CADHERINS; CALCIUM; CARDIOMYOPATHIES; CELLS, CULTURED; CONNEXIN 43; DISEASE MODELS, ANIMAL; DOXORUBICIN; HUMANS; MEMBRANE POTENTIALS; MICE; MICE, TRANSGENIC; MYOCARDIUM; MYOCYTES, CARDIAC; RECEPTOR, ADENOSINE A2A;

EID: 77952643019     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00688.2009     Document Type: Article

References (53)

1. Akar FG, Spragg DD, Tunin RS, Kass DA, Tomaselli GF. Mechanisms underlying conduction slowing and arrhythmogenesis in nonischemic dilated cardiomyopathy. Circ Res 95: 717-725, 2004.
2. Beardslee MA, Lerner DL, Tadros PN, Laing JG, Beyer EC, Yamada KA, Kleber AG, Schuessler RB, Saffitz JE. Dephosphorylation and intracellular redistribution of ventricular connexin43 during electrical uncoupling induced by ischemia. Circ Res 87: 656-662, 2000.
3. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sageman WS, Daniels JR. Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances. Lab Invest 45: 157-168, 1981.
4. Buja LM, Ferrans VJ, Mayer RJ, Roberts WC, Henderson E. Cardiac ultrastnictural changes induced by daunorubicin therapy. Cancer 32: 771-778, 1973.
5. 1-adenosine receptor. Clin Transl Sci 1: 126-133, 2008.
6. Drury A, Szent-Györgyi A. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J Physiol 68: 213-237, 1929.
7. Ferreira-Cornwell MC, Luo Y, Narula N, Lenox JM, Lieberman M, Radice GL. Remodeling the intercalated disc leads to cardiomyopathy in mice misexpressing cadherins in the heart. J Cell Sci 115: 1623-1634, 2002. (Pubitemid 34520592)
8. Friess GG, Boyd JF, Geer MR, Garcia JC. Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. Cancer 56: 2762-2764, 1985.
9. Funakoshi H, Chan TO, Good JC, Libonati JR, Piuhola J, Chen X, MacDonnell SM, Lee LL, Herrmann DE, Zhang J, Martini J, Palmer TM, Sanbe A, Robbins J, Houser SR, Koch WJ, Feldman AM. Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 114: 2240-2250, 2006. (Pubitemid 44789499)
10. Gianni D, Chan J, Gwathmey JK, del Monte F, Hajjar RJ. SERCA2a in heart failure: role and therapeutic prospects. J Bioenerg Biomembr 37: 375-380, 2005. (Pubitemid 43725161)
11. Gosalvez M, van Rossum GD, Blanco MF. Inhibition of sodium-potassium- activated adenosine 5′-triphosphatase and ion transport by adriamycin. Cancer Res 39: 257-261, 1979. (Pubitemid 9090441)
12. Gutstein DE, Morley GE, Fishman GI. Conditional gene targeting of connexin43: exploring the consequences of gap junction remodeling in the heart. Cell Commun Adhes 8: 345-348, 2001. (Pubitemid 135749825)
13. Gutstein DE, Morley GE, Tamaddon H, Vaidya D, Schneider MD, Chen J, Chien KR, Stuhlmann H, Fishman GI. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 88: 333-339, 2001. (Pubitemid 32173758)
14. Gutstein DE, Morley GE, Vaidya D, Liu F, Chen FL, Stuhlmann H, Fishman GI. Heterogeneous expression of Gap junction channels in the heart leads to conduction defects and ventricular dysfunction. Circulation 104: 1194-1199, 2001. (Pubitemid 32830407)
15. Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 285: H1797-H1818, 2003.
16. Hosenpud JD, Greenberg BH. Congestive Heart Failure. Philadelphia, PA: Lippincott Williams & Wilkins, 2006.
17. Ito H, Miller SC, Billingham ME, Akimoto H, Torti SV, Wade R, Gahlmann R, Lyons G, Kedes L, Torti FM. Doxorubicin selectively inhibits muscle gene expression in cardiac muscle cells in vivo and in vitro. PNAS 87: 4275-4279 1990.
18. Jeyaseelan R, Poizat C, Wu HY, Kedes L. Molecular mechanisms of doxorubicin-induced cardiomyopathy. J Biol Chem 272: 5828-5832, 1997.
19. Kang KY, Chen Y, Yu A, Voss-McCowan M, Epstein PN. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506, 1997. (Pubitemid 27425776)
20. Kilickap S, Akgul E, Aksoy S, Atymir K, Barista I. Doxorubicin-induced second degree and complete atrioventricular block. Europace 7: 227-230, 2005. (Pubitemid 40614359)
21. Kitakaze M. Doxorubicin, to treat cancers or to cause cardiac injury, that is the question. Cardiovasc Drugs Ther 15: 199-200, 2001. (Pubitemid 33010599)
22. Klugmann FB, Decorti G, Candussio L, Grill V, Mallardi F, Baldini L. Inhibitors of adriamycin-induced histamine release in vitro limit adriamycin cardiotoxicity in vivo. Br J Cancer 54: 743-748, 1986. (Pubitemid 17177531)
23. Li J, Levin MD, Xiong Y, Petrenko N, Patel VV, Radice GL. N-cadherin haploinsufficiency affects cardiac gap junctions and arrhythmic susceptibility. J Mol Cell Cardiol 44: 597-606, 2008.
24. Li J, Patel VV, Kostetskii I, Xiong Y, Chu AF, Jacobson JT, Yu C, Morley GE, Molkentin JD, Radice GL. Cardiac-specific loss of N-cadherin leads to alteration in connexins with conduction slowing and arrhythmogenesis. Circ Res 97: 474-481, 2005. (Pubitemid 41298178)
25. Michael G, Xiao L, Qi XY, Dobrev D, Nattel S. Remodelling of cardiac repolarization: how homeostatic responses can lead to arrhythmogenesis. Cardiovasc Res 81: 491-499, 2009.
26. Mori Y, Higuchi M, Masuyama N, Gotoh Y. Adenosine A2A receptor facilitates calcium-dependent protein secretion through the activation of protein kinase A and phosphatidylinositol-3 kinase in PC12 cells. Cell Struct Funct 29: 101-110, 2004. (Pubitemid 40260034)
27. Most PSH, Gao E, Funakoshi H, Volkers M, Heierhorst J, Remppis A, Pleger ST, DeGeorge BR Jr, Eckhart AD, Feldman AM, Koch WJ. Cardiac S100A1 protein levels determine contractile performance and propensity toward heart failure after myocardial infarction. Circulation 114: 1258-1268, 2006. (Pubitemid 44402051)
28. Myers CE, McGuire WP, Liss KH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167, 1977.
29. Nosir YF, Vletter WB, Kasprzak JD, Boersma E, Lequin MH, Elhendy AA, Yao J, Stoker J, Ten Cate FJ, Roelandt JR. Optimal rotational interval for 3-dimensional echocardiography data acquisition for rapid and accurate measurement of left ventricular function. J Am Soc Echocardiogr 13: 715-722, 2000. (Pubitemid 30651136)
30. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005. (Pubitemid 41464705)
31. 2+ exchanger expression and function in an arrhythmogenic rabbit model of heart failure. Circ Res 85: 1009-1019, 1999.
32. Saeki K, Obi I, Ogiku N, Shigekawa M, Imagawa T, Matsumoto T. Doxorubicin directly binds to the cardiac-type ryanodine receptor. Life Sci 70: 2377-2389, 2002. (Pubitemid 34261048)
33. Sgoifo A, Stilli D, Medici D, Gallo P, Aimi B, Musso E. Electrode positioning for reliable telemetry ECG recordings during social stress in unrestrained rats. Physiol Behav 60: 1397-1401, 1996. (Pubitemid 26418523)
34. Singal PK, Deally CM, Weinberg E. Subcellular effects of adriamycin in the heart: a concise review. Mol Cell Cardiol 19: 817-828, 1987.
35. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
36. Singal PK, Panagia V. Direct effects of adriamycin on the rat heart sarcolemma. Res Commun Chem Pathol Pharmacol 43: 67-77, 1984. (Pubitemid 14188694)
37. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol Heart Circ Physiol 250: H419-H425, 1986.
38. Singal PK, Segstro RJ, Singh RP, Kutryk MJ. Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. J Cardiol 1: 139-147, 1985. (Pubitemid 15235351)
39. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001. (Pubitemid 32222155)
40. Solan JL, Lampe PD. Connexin phosphorylation as a regulatory event linked to gap junction channel assembly. Biochim Biophys Acta 1711: 154-163, 2005.
41. Sommerschild HT, Kirkeboen KA. Adenosine and cardioprotection during ischaemia and reperfusion - an overview. Acta Anaesthesiol Scand 44: 1038-1055, 2000.
42. 2+ regulation in rats with doxorubicin-induced cardiomyopathy. J Am Coll Cardiol 44: 2239-2246, 2004.
43. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 20: 333-353, 1967.
44. Todd J, Zhao ZQ, Williams MW, Sato H, Van Wylen DG, Vinten-Johansen J. Intravascular adenosine at reperfusion reduces infarct size and neutrophil adherence. Ann Thorac Surg 62: 1364-1372, 1996. (Pubitemid 26383533)
45. Torti FM, Bristow MM, Lum BL, Carter SK, Howes AE, Aston DA, Brown BW Jr, Hannigan JF Jr, Meyers FJ, Mitchell EP, and Billingham ME. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial. Biopsy Cancer Res 46: 3722-3727, 1986.
46. 2+ exchange. Am J Physiol Heart Circ Physiol 291: H2199-H2209, 2006.
47. Umlauf J, Horky M. Molecular biology of doxorubicin-induced cardiomyopathy. Exp Clin Cardiol 7: 35-39, 2002.
48. Vinten-Johansen J, Thourani VH, Ronson RS, Jordan JE, Zhao ZQ, Nakamura M, Velez D, Guyton RA. Broad-spectrum cardioprotection with adenosine. Ann Thorac Surg 68: 1942-1948, 1999.
49. Wyatt AW, Steinert JR, Wheeler-Jones CP, Morgan AJ, Sugden D, Pearson JD, Sobrevia L, Mann GE. Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J 16: 1584-1594, 2002. (Pubitemid 35154641)
50. Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116: 1913-1923, 2006.
51. Yi X, Bekeredjian R, DeFilippis NJ, Siddiquee Z, Fernandez E, Shohet RV. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol 290: H1098-H1102, 2006.
52. 2A-adenosine receptor: a GPCR with unique features? Br J Pharmacol 153, Suppl 1: S184-S190, 2008.
53. 2+ content in adult rat myocytes. Am J Physiol Heart Circ Physiol 281: H2079-H2088, 2001.